Want to see NRIX full AI Analyst Report?
NRIX Stock Chart & Stats
$17.51
$0.42(2.22%)
At close: 4:00 PM EST
$17.51
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.20 - $25.09
Previous CloseN/A
Volume302.00K
Average Volume (3M)2.93M
Market Cap
$2.55B
Enterprise Value$1.47B
Total Cash (Recent Filing)$443.53M
Total Debt (Recent Filing)$58.14M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Feb 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding103,405,815
10 Day Avg. Volume2,320,679
30 Day Avg. Volume2,925,495
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue40.02
Enterprise Value/Gross Profit-22.28
Enterprise Value/Ebitda-4.49
Forecast
1Y Price Target
$34.18Price Target Upside95.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.5
Revenue Forecast (FY)$102.90M
Bulls Say, Bears Say
Bulls Say
Strategic Roche CollaborationThe global Roche license and co-development/co-commercialization agreement provides a $700M upfront and up to $2.3B in payments, materially extending runway. Roche’s global infrastructure and cost-sharing reduce Nurix’s execution and commercialization burden, accelerating pivotal programs and lowering funding risk.
Differentiated Phase 1b Clinical DataRobust efficacy and tolerability for bexobrutideg across difficult-to-treat and earlier-line cohorts support the asset’s potential best-in-class positioning. Durable responses and CNS penetration increase the probability of successful pivotal trials and broaden indications into oncology and immunology, strengthening long-term commercial prospects.
Modest Leverage And Sizable Asset BaseLow debt-to-equity (~0.14) and sizable assets give Nurix financial flexibility. Combined with partnership payments, this conservative capital structure reduces insolvency risk and supports continued R&D spend and trial execution over the medium term, absent catastrophic setbacks.
Bears Say
High Persistent Cash BurnSustained negative operating and free cash flow at scale signals ongoing reliance on external funding or milestone receipts. This persistent burn increases dilution and constrains strategic optionality, making program pacing and capital allocation sensitive to partner payments and financing markets.
Shrinking Revenue And Widening LossesA steep revenue decline alongside materially wider losses underscores limited internal revenue generation and negative margins. Without commercial products, deteriorating top-line and heavy losses reduce self-funding ability and increase dependence on partnerships and capital raises to advance late-stage programs.
Dependence On Partnership Model And Deal ContingenciesNurix’s model depends on upstream licensing and milestone flows rather than product sales. Strategic outcomes hinge on partner execution, regulatory/antitrust approvals and milestone timing; setbacks or altered terms can delay funding and commercialization, concentrating revenue and execution risk externally.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics, Inc.’s price range in the past 12 months?
Nurix Therapeutics, Inc. lowest stock price was $8.20 and its highest was $25.09 in the past 12 months.
What is Nurix Therapeutics, Inc.’s market cap?
Nurix Therapeutics, Inc.’s market cap is $2.55B.
When is Nurix Therapeutics, Inc.’s upcoming earnings report date?
Nurix Therapeutics, Inc.’s upcoming earnings report date is Feb 17, 2027 which is in 221 days.
How were Nurix Therapeutics, Inc.’s earnings last quarter?
Nurix Therapeutics, Inc. released its earnings results on Jul 09, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.723 by -$0.087.
Is Nurix Therapeutics, Inc. overvalued?
According to Wall Street analysts Nurix Therapeutics, Inc.’s price is currently Undervalued.
Does Nurix Therapeutics, Inc. pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
What is Nurix Therapeutics, Inc.’s EPS estimate?
Nurix Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nurix Therapeutics, Inc. have?
Nurix Therapeutics, Inc. has 103,405,815 shares outstanding.
What happened to Nurix Therapeutics, Inc.’s price movement after its last earnings report?
Nurix Therapeutics, Inc. reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.723. Following the earnings report the stock price went down -6.602%.
Which hedge fund is a major shareholder of Nurix Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.18 (95.21% Upside)
$34.18 (95.21% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 658.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.32%
12-Months-Change
Fundamentals
Return on Equity
-64.21%
Trailing 12-Months
Asset Growth
3.43%
Trailing 12-Months
Company Description
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX Stock 12 Month Forecast
Average Price Target
$34.18
▲(95.21% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
17.97% Mutual Funds
0.14% Other Institutional Investors
65.09% Public Companies and
Individual Investors